Evidence map›Paper›PMID 35701387›Full record

ArticleThe British journal of dermatology2022

Common genetic variants associated with melanoma risk or naevus count in patients with wildtype MC1R melanoma.

Neus Calbet-Llopart, Marc Combalia, Anil Kiroglu, Miriam Potrony, Gemma Tell-Martí, Andrea Combalia, Albert Brugues, Sebastian Podlipnik, Cristina Carrera, Susana Puig and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. GermlineBiomolecules · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Neus Calbet-LlopartDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-0443-3025
Marc CombaliaDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-5237-4256
Anil KirogluDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-9360-4142
Miriam PotronyCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0003-2766-0765
Gemma Tell-MartíDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-2728-6961
Andrea CombaliaDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-0583-9000
Albert BruguesDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-0543-9405
Sebastian PodlipnikDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-4150-0522
Cristina CarreraDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-1608-8820
Susana PuigDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-1337-9745
Josep MalvehyDermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-6998-914X
Joan Anton Puig-ButilléCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0003-4345-9631
Instituto de Salud Carlos III · ESHospital Clínic de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypomorphic MC1R variants are the most prevalent genetic determinants of melanoma risk in the white population. However, the genetic background of patients with wildtype (WT) MC1R melanoma is poorly studied.

objectivesTo analyse the role of candidate common genetic variants on the melanoma risk and naevus count in Spanish patients with WT MC1R melanoma.

methodsWe examined 753 individuals with WT MC1R from Spain (497 patients and 256 controls). We used OpenArray reverse-transcriptase polymerase chain reaction to genotype a panel of 221 common genetic variants involved in melanoma, naevogenesis, hormonal pathways and proinflammatory pathways. Genetic models were tested using multivariate logistic regression models. Nonparametric multifactor dimensionality reduction (MDR) was used to detect gene-gene interactions within each biological subgroup of variants.

resultsWe found that variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increased melanoma risk in individuals with WT MC1R [odds ratio (OR) 1·97, 95% confidence interval (CI) 1·48-2·63; adjusted P < 0·001; corrected P < 0·001]. We also observed a trend between the rs3798577 variant in the oestrogen receptor alpha gene (ESR1) and a lower naevus count, which was restricted to female patients with WT MC1R (OR 0·51, 95% CI 0·33-0·79; adjusted P = 0·002; corrected P = 0·11). This sex-dependent association was statistically significant in a larger cohort of patients with melanoma regardless of their MC1R status (n = 1497; OR 0·71, 95% CI 0·57-0·88; adjusted P = 0·002), reinforcing the hypothesis of an association between hormonal pathways and susceptibility to melanocytic proliferation. Last, the MDR analysis revealed four genetic combinations associated with melanoma risk or naevus count in patients with WT MC1R.

conclusionsOur data suggest that epistatic interaction among common variants related to melanocyte biology or proinflammatory pathways might influence melanocytic proliferation in individuals with WT MC1R. What is already known about this topic? Genetic variants in the MC1R gene are the most prevalent melanoma genetic risk factor in the white population. Still, 20-40% of cases of melanoma occur in individuals with wildtype MC1R. Multiple genetic variants have a pleiotropic effect in melanoma and naevogenesis. Additional variants in unexplored pathways might also have a role in melanocytic proliferation in these patients. Epidemiological evidence suggests an association of melanocytic proliferation with hormonal pathways and proinflammatory pathways. What does this study add? Variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increases the melanoma risk in individuals with wildtype MC1R. Variant rs3798577 in the oestrogen receptor gene is associated with naevus count regardless of the MC1R status in female patients with melanoma. We report epistatic interactions among common genetic variants with a role in modulating the risk of melanoma or the number of naevi in individuals with wildtype MC1R. What is the translational message? We report a potential role of hormonal signalling pathways in melanocytic proliferation, providing a basis for better understanding of sex-based differences observed at the epidemiological level. We show that gene-gene interactions among common genetic variants might be responsible for an increased risk for melanoma development in individuals with a low-risk phenotype, such as darkly pigmented hair and skin.

Indexed as

MelanomaNevus, PigmentedSkin NeoplasmsFemaleGenotypeHumansReceptor, Melanocortin, Type 1Risk FactorsReceptor, Melanocortin, Type 1

Identifiers

PMID35701387
PMCPMC9804579
OpenAlexW4282935445

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.